Evidence map›Paper›PMID 37712113›Full record

ArticleAddiction (Abingdon, England)2024

Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder.

Canyon Foot, Philip T Korthuis, Judith I Tsui, Sean X Luo, Brian Chan, Ryan R Cook

Open access · bronzeAbstract read
In one paragraph

Article in Addiction (Abingdon, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Canyon FootDepartment of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA.
Philip T KorthuisDepartment of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-5556-3597
Judith I TsuiDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0003-0877-5399
Sean X LuoDivision on Substance Use Disorders, Department of Psychiatry, Columbia University, New York, NY, USA.
Brian ChanDepartment of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA.
Ryan R CookDepartment of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-8754-995X
Oregon Health & Science University · USNational Center on Addiction and Substance Abuse at Columbia University · USUniversity of Washington · US

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
NW Center of Excellence & K12 in Patient Centered Learning Health Systems ScienceK12HS026370 · AHRQ · OREGON HEALTH & SCIENCE UNIVERSITY · PI EDEN, KAREN BEEKMAN, GUISE, JEANNE-MARIE · 2018 to 2022
$4.0M
Identifying High Utilizing Patients with Opioid Use Disorder to Engage in Primary CareK23DA053390 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Brian Chan · 2022 to 2026
$886k
Transporting treatment effects from clinical trials to real-world populations with co-occurring opioid and stimulant use disordersK01DA055130 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI COOK, RYAN · 2022 to 2025
$714k
AHRQ HHS K12 HS026370NIDA NIH HHS K01 DA055130NIDA NIH HHS K01DA055130NIDA NIH HHS K23 DA053390NIDA NIH HHS L30 DA054663NIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1DA015831
6 · The paper itself

Abstract

aimThe aim of this study was to estimate how ongoing stimulant use affects return to illicit opioid use after initiation onto medication for opioid use disorder (MOUD).

designThis was a secondary analysis of pooled data from two clinical trials comparing buprenorphine (BUP-NX) and extended-release naltrexone (XR-NTX).

settingThirteen opioid treatment programs and HIV clinics across 10 states in the United States from 2014 to 2019 took part in this study.

participantsA total of 528 participants who initiated MOUD as part of trial participation were included. Nearly half (49%) were between 30 and 49 years of age, 69% were male and 66% were non-Hispanic White. MEASUREMENTS: The primary outcome was first self-reported day of non-prescribed opioid use following MOUD initiation, and the exposure of interest was daily stimulant use (methamphetamine, amphetamines or cocaine). Both were defined using time-line follow-back. Among participants reporting at least 1 day of illicit opioid use, we also examined relapse to ongoing use, defined as (1) 7 days of continuous opioid use or (2) 4 consecutive weeks with self-reported opioid use, one or more positive urine drug screens (UDS) for opioids or one or more missing UDS.

findingsForty-seven per cent of participants reported stimulant use following MOUD initiation, 58% returned to illicit opioid use and 66% of those relapsed to ongoing use. Stimulant use was strongly associated with increased risk of misusing opioids after MOUD initiation when measured daily [adjusted hazard ratio (aHR) = 9.23, 95% confidence interval (CI) = 6.80-12.50, P < 0.001] and over a 7-day period (aHR = 1.27 for each additional day, CI = 1.18-1.37, P < 0.001). Using stimulants weekly or more often was associated with increased likelihood of relapse to ongoing opioid use compared with less than weekly or no stimulant use (adjusted odds ratio = 2.30, CI = 1.05-5.39, P = 0.044).

conclusionsPeople initiated on medication for opioid use disorder who subsequently use stimulants appear to be more likely to return to and continue using non-prescribed opioids compared with those without stimulant use. The association appears to be stronger among patients who initiate buprenorphine compared with those who initiate extended-release naltrexone.

Indexed as

Central Nervous System StimulantsOpioid-Related DisordersAdultAnalgesics, OpioidBuprenorphineClinical Trials as TopicDelayed-Action PreparationsFemaleHumansMaleMiddle AgedNaltrexoneRecurrenceUnited StatesAnalgesics, OpioidBuprenorphineCentral Nervous System StimulantsDelayed-Action PreparationsNaltrexoneBuprenorphineextended-release naltrexonemedications for opioid use disorderopioidsrelapsestimulants

Identifiers

PMID37712113
PMCPMC11139042
OpenAlexW4386757551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.